Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning

Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children

Bone Marrow Transplantation volume 51, pages 72–78 (2016)Cite this article

Subjects

Abstract

Busulfan, the corner stone of hematopoietic stem cell transplantation regimens, has a narrow therapeutic window. Therapeutic drug monitoring (TDM)-guided dosing to reach the conventional area under the concentration–time curve (AUC) target range of 900–1500 μmol min/L is associated with better outcomes. We report our experience with busulfan TDM in a large cohort of children. The aims were to investigate the relevance of using a more restricted therapeutic range and investigate the association between busulfan therapeutic range and clinical outcome. This study includes 138 children receiving 16 doses of intravenous busulfan, with the first dose assigned based on weight and doses adjusted to a local AUC target range of 980–1250 μmol min/L. Busulfan TDM combined with model-based dose adjustment was associated with an increased probability of AUC target attainment, for both target range: 90.8% versus 74.8% for the conventional target range and 66.2% versus 43.9% for the local target range (P<0.001). The median follow-up was 56.2 months. Event-free survival was 88.5%, overall survival was 91.5% and veno-occlusive disease occurred in 18.3% of patients. No difference was observed for clinical outcomes depending on the selected target range. Pharmacokinetic monitoring and individualization of busulfan dosage regimen are useful in improving target attainment, but using a restricted target range has no impact on clinical outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

    Article  CAS  PubMed  Google Scholar 

  2. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944–950.

    Article  CAS  PubMed  Google Scholar 

  3. Cohen A, Békássy AN, Gaiero A, Faraci M, Zecca S, Tichelli A et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41: S43–S48.

    Article  CAS  PubMed  Google Scholar 

  4. Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63: 1568–1575.

    Article  PubMed  Google Scholar 

  5. Faraci M, Békássy AN, De Fazio V, Tichelli A, Dini G, EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 41: S49–S57.

    Article  CAS  PubMed  Google Scholar 

  6. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167–173.

    Article  CAS  PubMed  Google Scholar 

  7. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.

    CAS  PubMed  Google Scholar 

  8. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121–1124.

    Article  CAS  PubMed  Google Scholar 

  9. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.

    Article  CAS  PubMed  Google Scholar 

  10. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.

    CAS  PubMed  Google Scholar 

  11. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743–751.

    Article  CAS  PubMed  Google Scholar 

  12. De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    Article  CAS  PubMed  Google Scholar 

  13. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220–228.

    Article  CAS  PubMed  Google Scholar 

  14. Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150.

    CAS  PubMed  Google Scholar 

  15. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477–485.

    Article  CAS  PubMed  Google Scholar 

  16. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386–389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 805–812.

    Article  CAS  PubMed  Google Scholar 

  18. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C . I.V.busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979–987.

    Article  CAS  PubMed  Google Scholar 

  19. Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113–123.

    Article  CAS  PubMed  Google Scholar 

  20. Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17–23.

    Article  CAS  PubMed  Google Scholar 

  21. Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T . Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant 2011; 15: 580–588.

    PubMed  Google Scholar 

  22. Michel G, Valteau-Couanet D, Gentet J-C, Esperou H, Socié G, Méchinaud F et al. Weight-based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results. Pediatr Blood Cancer 2012; 58: 90–97.

    Article  PubMed  Google Scholar 

  23. Tesfaye H, Branova R, Klapkova E, Prusa R, Janeckova D, Riha P et al. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children. Ann Transplant 2014; 19: 214–224.

    Article  CAS  PubMed  Google Scholar 

  24. Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163: 444–457.

    Article  CAS  PubMed  Google Scholar 

  25. Bleyzac N, Barou P, Aulagner G . Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl 2000; 742: 427–432.

    Article  CAS  PubMed  Google Scholar 

  26. Dos Reis EO, Vianna-Jorge R, Suarez-Kurtz G, Lima EL, da S, Azevedo D de A . Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 1666–1674.

    Article  CAS  PubMed  Google Scholar 

  27. D’Argenio DZ . Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–756.

    Article  PubMed  Google Scholar 

  28. Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit 2007; 29: 177–184.

    Article  CAS  PubMed  Google Scholar 

  29. Jelliffe RW . The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care 1991: 922–924.

  30. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463–470.

    Article  CAS  PubMed  Google Scholar 

  31. Galambrun C, Pondarré C, Bertrand Y, Loundou A, Bordigoni P, Frange P et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant 2013; 19: 62–68.

    Article  PubMed  Google Scholar 

  32. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  33. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005–3020.

    CAS  PubMed  Google Scholar 

  34. Nath CE, Shaw PJ . Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007; 2: 75–91.

    Article  CAS  PubMed  Google Scholar 

  35. Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 307–314.

    Article  CAS  PubMed  Google Scholar 

  36. Zwaveling J, den Hartigh J, Lankester AC, Guchelaar H-J, Egeler RM, Bredius RG et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 2006; 17: 1099–1105.

    Article  CAS  PubMed  Google Scholar 

  37. Ljungman P, Hassan M, Békássy AN, Ringdén O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909–913.

    Article  CAS  PubMed  Google Scholar 

  38. Paci A, Vassal G, Moshous D, Dalle J-H, Bleyzac N, Neven B et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit 2012; 34: 198–208.

    Article  CAS  PubMed  Google Scholar 

  39. Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant 2014; 18: 294–301.

    Article  CAS  PubMed  Google Scholar 

  40. Bartelink IH, Bredius RGM, Belitser SV, Suttorp MM, Bierings M, Knibbe CAJ et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 231–241.

    Article  CAS  PubMed  Google Scholar 

  41. Buffery PJ, Allen KM, Chin PKL, Moore GA, Barclay ML, Begg EJ . Thirteen years’ experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Ther Drug Monit 2014; 36: 86–92.

    CAS  PubMed  Google Scholar 

  42. Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 2014; 36: 93–99.

    CAS  PubMed  Google Scholar 

  43. Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010; 54: 291–298.

    PubMed  Google Scholar 

  44. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396–1404.

    PubMed  Google Scholar 

  45. Cheuk DKL, Wang P, Lee TL, Chiang AKS, Ha SY, Lau YL et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 935–944.

    Article  CAS  PubMed  Google Scholar 

  46. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE . Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–1167.

    Article  CAS  PubMed  Google Scholar 

  47. Hines RN . The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118: 250–267.

    Article  CAS  PubMed  Google Scholar 

  48. Kim AH, Tse JC, Ikeda A, Moore TB . Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. Pediatr Transplant 2009; 13: 971–976.

    Article  CAS  PubMed  Google Scholar 

  49. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT . Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509–5516.

    CAS  PubMed  Google Scholar 

  50. Savic RM, Cowan MJ, Dvorak CC, Pai S-Y, Pereira L, Bartelink IH et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1608–1614.

    Article  CAS  PubMed  Google Scholar 

  51. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT . Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos Biol Fate Chem 1999; 27: 1466–1469.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Institute of Pediatric Hematology and Oncology, and Hospices Civils de Lyon, Lyon, France

    M Philippe, C Bergeron, Y Bertrand & N Bleyzac

  2. Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558, Université Lyon 1, Villeurbanne, France

    M Philippe, S Goutelle & N Bleyzac

  3. ISPB - Faculté de Pharmacie de Lyon, Université Lyon 1, Lyon, France

    S Goutelle & J Guitton

  4. Service Pharmaceutique, Groupement Hospitalier de Gériatrie, Hospices Civils de Lyon, Lyon, France

    S Goutelle

  5. Laboratoire de Ciblage Thérapeutique en Cancérologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France

    J Guitton

  6. Laboratoire de Pharmacologie, University Hospital Centre, Grenoble, France

    X Fonrose

  7. Clinique de Pédiatrie, Hôpital Couple Enfant, University Hospital Centre, Grenoble, France

    P Girard

Authors
  1. M Philippe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Goutelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Guitton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X Fonrose
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Bergeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N Bleyzac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Bleyzac.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Philippe, M., Goutelle, S., Guitton, J. et al. Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children. Bone Marrow Transplant 51, 72–78 (2016). https://doi.org/10.1038/bmt.2015.218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.218

This article is cited by

Search

Advanced search

Quick links